Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.62 |
| ▸ | CA1 | P00915 | 3/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA7 | P43166 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 2/20 | 0.50 |
| ▸ | KLK1 | P06870 | 2/20 | 0.50 |
| ▸ | KLK6 | Q92876 | 2/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29637890 | 1.00 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13609957 | 0.88 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3157053 | 0.86 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14168030 | 0.86 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23645185 | 0.85 | CFTR (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13280707 | 0.84 | CFTR (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4397432 | 0.83 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8081709 | 0.83 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10744053 | 0.82 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13609971 | 0.82 | CA12 (0.54) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111574368-B | Synthesis method of methyl 5-tert-butyl-2-hydroxybenzoate | 西安瑞联新材料股份有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-111574368-A | Synthesis method of methyl 5-tert-butyl-2-hydroxybenzoate | 西安瑞联新材料股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| US-20250288563-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2025-09-18 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4484402-A2 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-3717455-B1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12024491-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024491-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024491-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240166607-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-05-23 | — | — | US | disclosed |
| CN-117924170-A | Methods for preparing modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-7294720-B2 | Opioid receptor active compounds | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294720-B2 | Opioid receptor active compounds | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294720-B2 | Opioid receptor active compounds | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2007-11-13 | — | — | US | disclosed |
| US-20060128776-A1 | Opioid receptor active compounds | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2006-06-15 | — | — | US | disclosed |
| US-7045520-B2 | Opioid receptor active compounds | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2006-05-16 | — | — | US | disclosed |
| EP-1485088-A1 | OPIOID RECEPTOR ACTIVE 4-(3-HYDROXYPHENYL) OR 4-(3-ALKOXYPHENYL)-1,2,4-TRIAZOLE COMPOUNDS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20030225072-A1 | Opioid receptor active compounds | CURATORS OF THE UNIVERSITY OF MISSOURI, THE | 2003-12-04 | — | — | US | disclosed |
| WO-2003066050-A1 | OPIOID RECEPTOR ACTIVE 4-(3-HYDROXYPHENYL) OR 4-(3-ALKOXYPHENYL)-1,2,4-TRIAZOLE COMPOUNDS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2003-08-14 | — | — | WO | disclosed |
| US-4923865-A | Substituted 1-(1H-imidazol-4-yl)alkyl-benzamides as anti-ischemics and as alpha-2-adrenergic receptor agonists | U C B SOCIETE ANONYME (BE) | 1990-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225072-A1 | Opioid receptor active compounds | OPRL1, OPRM1, OPRK1 | CA12 4511/4885CA1 3616/4885CA2 2746/4885 |
| US-12024491-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SLC47A2, SCNN1B | CA12 4735/4885CA1 4876/4885CA2 3359/4885 |
| US-20240166607-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC47A2, SCNN1B | CA12 4735/4885CA1 4876/4885CA2 3359/4885 |
| US-20060128776-A1 | Opioid receptor active compounds | OPRL1, OPRM1, OPRK1 | CA12 4199/4885CA1 3741/4885CA2 2515/4885 |
| US-20250288563-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, SLC26A4, SCNN1B | CA12 2511/4885CA1 4396/4885CA2 580/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | CA12 4808/4885CA1 4853/4885CA2 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.